Temozolomide as salvage treatment in primary brain lymphomas.
Standard
Temozolomide as salvage treatment in primary brain lymphomas. / Reni, M; Zaja, F; Mason, W; Perry, J; Mazza, E; Spina, M; Bordonaro, R; Ilariucci, F; Faedi, M; Corazzelli, G; Manno, P; Franceschi, E; Pace, Andrea; Candela, M; Abbadessa, A; Stelitano, C; Latte, G; Ferreri, A J M.
In: BRIT J CANCER, Vol. 96, No. 6, 6, 2007, p. 864-867.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Temozolomide as salvage treatment in primary brain lymphomas.
AU - Reni, M
AU - Zaja, F
AU - Mason, W
AU - Perry, J
AU - Mazza, E
AU - Spina, M
AU - Bordonaro, R
AU - Ilariucci, F
AU - Faedi, M
AU - Corazzelli, G
AU - Manno, P
AU - Franceschi, E
AU - Pace, Andrea
AU - Candela, M
AU - Abbadessa, A
AU - Stelitano, C
AU - Latte, G
AU - Ferreri, A J M
PY - 2007
Y1 - 2007
N2 - Methotrexate (MTX)-based chemotherapy extends survival in patients with primary brain lymphomas, but it is not clear whether multiagent chemotherapy is superior to MTX alone. Treatment options for patients with recurrent primary brain lymphoma are limited; there is no standard second-line chemotherapy. New chemotherapeutic agents with clear activity in brain lymphoma are needed for treatment of recurrent disease. We report the results of a phase II trial assessing activity of the alkylating agent temozolomide in immunocompetent patients with recurrent primary brain lymphomas, previously treated with high-dose MTX-containing chemotherapy and/or radiotherapy. A median of two courses (range 1-12) of temozolomide 150 mg m-2 day-1, for 5 days every 4 weeks was administered to 36 patients yielding nine complete and two partial responses (response rate: 31%; 95% confidence interval 16-46%). One-year survival was 31% (95% confidence interval 16-46%). Toxicity was negligible. We conclude that temozolomide is active in recurrent primary brain lymphomas and should further be evaluated in this disease, perhaps in combination with MTX as initial treatment.
AB - Methotrexate (MTX)-based chemotherapy extends survival in patients with primary brain lymphomas, but it is not clear whether multiagent chemotherapy is superior to MTX alone. Treatment options for patients with recurrent primary brain lymphoma are limited; there is no standard second-line chemotherapy. New chemotherapeutic agents with clear activity in brain lymphoma are needed for treatment of recurrent disease. We report the results of a phase II trial assessing activity of the alkylating agent temozolomide in immunocompetent patients with recurrent primary brain lymphomas, previously treated with high-dose MTX-containing chemotherapy and/or radiotherapy. A median of two courses (range 1-12) of temozolomide 150 mg m-2 day-1, for 5 days every 4 weeks was administered to 36 patients yielding nine complete and two partial responses (response rate: 31%; 95% confidence interval 16-46%). One-year survival was 31% (95% confidence interval 16-46%). Toxicity was negligible. We conclude that temozolomide is active in recurrent primary brain lymphomas and should further be evaluated in this disease, perhaps in combination with MTX as initial treatment.
M3 - SCORING: Zeitschriftenaufsatz
VL - 96
SP - 864
EP - 867
JO - BRIT J CANCER
JF - BRIT J CANCER
SN - 0007-0920
IS - 6
M1 - 6
ER -
